Robert W. Baird Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target raised by analysts at Robert W. Baird from $7.00 to $9.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price objective suggests a potential downside of 3.23% […]
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target raised by analysts at Robert W. Baird from $7.00 to $9.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price objective suggests a potential downside of 3.23% […]
-logo-1200x675.png?v=20230308140948&w=240&h=240&zc=2){kind=logo}
